Lexicon Pharma (LXRX) Tops Q2 EPS by 10c
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $2.02 -6.05%
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Subscription and license fees: 31K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of $0.01, $0.10 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $28.86 million versus the consensus estimate of $6.49 million.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Microsoft plans data center push to triple its computing power - Bloomberg
- Lightpath Technologies (LPTH) Misses Q4 EPS by 5c
- Grosvenor closes $5.25M subscription receipt private placement
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
